Journal
HUMAN PATHOLOGY
Volume 140, Issue -, Pages 144-172Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.humpath.2023.04.016
Keywords
Checkpoint inhibitor; Immunotherapy; PD-1; PD-L1; CTLA-4; Cutaneous; Drug rash
Categories
Ask authors/readers for more resources
Immune checkpoint inhibitors are a promising treatment option for cancer, but their off-target effects can cause immune-related cutaneous adverse events. Accurate diagnosis is crucial for timely and appropriate management.
Immune checkpoint inhibitors (ICIs) represent an emerging treatment option for a variety of cancer types. Through inhibition of programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and/or cytotoxic lymphocyte-associated antigen-4 (CTLA-4), ICIs activate the host's immune system causing a heightened anti-tumor response. However, off-target effects of ICIs can result in numerous different immune-related cutaneous adverse events (irCAEs). Beyond impacting quality of life, irCAEs can lead to dose limitations or discontinuation of anti-cancer therapies. Correct diagnosis is necessary for expedient and appropriate management. Skin biopsies are often performed to increase diagnostic accuracy and guide clinical management. An extensive literature review was per-formed using the PubMed database to identify the reported clinical and histopathologic features of ir-CAEs. This comprehensive review primarily details the histopathologic features of various irCAEs reported to date. Clinical presentation and immunopathogenesis are also discussed in relation to histo-pathology.(c) 2023 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available